Jacobio (1167.HK) has been selected and will be included as a constituent stock of the Hang Seng Composite Index (“HSCI”), announced by the Hang Seng Indexes Company Limited on Feb. 26 2021, with effect from 15 March 2021.
(Source：Press Release of Hang Seng Indexes Company)
Jacobio is focusing on drugging the undruggable, being enlisted as a constituent stock of the HSCI after its debut on Dec 2020, represents the capital market’s recognition of Jacobio’s research and development capability.
HSCI offers a comprehensive Hong Kong market benchmark that covers about the top 95th percentile of the total market capitalisation of companies listed on the Main Board of The Stock Exchange of Hong Kong Limited.HSCI increased 24.61% to 4585.32 during the past 12 months. Being selected as a constituent stock of the HSCI fulfills the eligibility criteria for the Southbound Trading under the Stock Connect Scheme, which is a channel that facilitates stock trading and investment between Hong Kong and a broader base of China Investors.
More information please visit Heng Seng Index Review Result https://www.hsi.com.hk/eng/newsroom/press-releases
Hang Seng Indexes Company Limited (‘Hang Seng Indexes Company’) manages and compiles the Hang Seng Family of Indexes, which cover stocks listed in Hong Kong and Mainland China. Our index series includes the Hang Seng Index, the Hang Seng China Enterprises Index and the Hang Seng TECH Index, as well as Stock Connect, Greater Bay Area and sector-related indexes. As at the end of 2020, assets under management in products passively tracking indexes in the Hang Seng Family of Indexes had reached a total of about US$38 billion. Hang Seng Indexes Company is a wholly owned subsidiary of Hang Seng Bank.
Jacobio Pharmaceuticals Co., Ltd., headquartered in Beijing, focuses on the R&D of innovative medicines, It dedicates to provide breakthrough innovations to treat major diseases and bring more solutions to promote human health. The vision of Jacobio is to become a global leader in pharmaceutical industry. Jacobio has established an R&D center in Boston, USA, to strengthen and coordinate the global development of new drugs.